|Bid||46.62 x 800|
|Ask||46.81 x 800|
|Day's Range||43.94 - 47.20|
|52 Week Range||33.06 - 82.68|
|Beta (3Y Monthly)||3.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||74.65|
ANN ARBOR, Mich., Oct. 18, 2018 -- Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,.
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.
Of the 22 analysts covering Spark Therapeutics in September, 11 of them have recommended a “buy” or higher, and nine have recommended a “hold.” Two analysts have given the stock a “sell” or lower rating. The mean rating for Spark stock is 2.41 with a target price of $69.67, implying an upside potential of 18% over its closing price of $59.04 on September 13. Its peers Esperion Therapeutics (ESPR), Intercept Pharmaceuticals (ICPT), and Axovant Sciences (AXON) have mean ratings of 2.27, 2.41, and 2.71, respectively, and target prices of $72.68, $123.07, and $4.70, respectively.
In September, there are seven analysts covering Axovant Sciences (AXON) stock. Two of them have given the stock a “buy” rating, and five have given it a “hold.” The mean rating for Axovant stock is 2.71 with a target price of $4.70, implying an upside potential of 129.3% over its trading price of $2.05 on September 11.
Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.
Esperion Therapeutics Inc said on Monday a combination of its drug, bempedoic acid, taken along with Merck's Zetia lowered cholesterol level by 35 percent in a late-stage study, sending the company's shares up as much as 11 percent. The 12-week study evaluated the efficacy and safety of the bempedoic acid-ezetimibe combination pill compared with bempedoic acid, ezetimibe or placebo in 382 high-risk patients. It showed a 35 percent reduction in low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, for the combination pill compared to a 3 percent for placebo, 24 percent for Zetia or ezetimibe, and 20 percent for bempedoic acid.
Esperion Therapeutics Inc. (espr) on Monday reported positive results in a late-stage trial of a treatment for patients with atherosclerotic cardiovascular disease (ASCVD). The company said the Phase 3 trial sought to evaluate the efficacy and safety of the bempedoic acid 180 mg / ezetimibe 10 mg combination pill compared to bempedoic acid, ezetimibe or placebo in patients treated with maximally tolerated statins. It also achieved a 34% reduction in high-sensitivity C-reactive protein (hsCRP), which the company said is an important marker of the underlying inflammation associated with cardiovascular disease.
—Bempedoic Acid/ Ezetimibe Combo Pill Achieved an Additional 35% LDL-C Lowering in Patients on Maximally Tolerated Statins—. —35% LDL-C Lowering Provides Potential for More Than 6 Million U.S. Patients ...
Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) gained about 1.5 percent. ...
—Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background of Maximally Tolerated Statins—. —Study 1 Provided the Largest Evidence to Date that Bempedoic Acid Is Safe when Added ...
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion ...
Biotech stocks continued to see lackluster sentiment this week. The upcoming week's catalytic events could have a major say in charting the course for biotech stocks. Stay tuned to the following events. ...
ANN ARBOR, Mich., Aug. 10, 2018-- Esperion, the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment ...
The Ann Arbor, Michigan-based company said it had a loss of $1.71 per share. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
ANN ARBOR, Mich., Aug. 02, 2018-- Esperion, the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment ...
An activist investor took the next step in acquiring his target. Conventional wisdom says insiders and 10 percent owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. International Flavors & Fragrances Inc (NYSE: IFF) saw beneficial owner Winder Investment add to its stake again.
Investors in Esperion Therapeutics (ESPR) need to pay close attention to the stock based on moves in the options market lately.